CVS Health (NYSE:CVS) Given New $118.00 Price Target at Truist Financial

CVS Health (NYSE:CVS) had its price objective hoisted by Truist Financial from $108.00 to $118.00 in a research report released on Tuesday morning, Marketbeat reports. Truist Financial currently has a buy rating on the pharmacy operator’s stock.

CVS has been the topic of a number of other reports. Cantor Fitzgerald boosted their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Argus raised their price objective on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Robert W. Baird boosted their target price on CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Piper Sandler restated an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Finally, TD Cowen increased their price target on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Twenty-one investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $104.04.

CVS Health Trading Up 0.2%

Shares of CVS stock opened at $106.11 on Tuesday. CVS Health has a 1 year low of $58.50 and a 1 year high of $106.93. The firm has a market capitalization of $135.39 billion, a PE ratio of 46.74, a price-to-earnings-growth ratio of 1.04 and a beta of 0.61. The stock has a fifty day moving average of $97.87 and a two-hundred day moving average of $84.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the company earned $2.25 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is 117.18%.

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in CVS Health during the fourth quarter valued at approximately $1,666,265,000. Wellington Management Group LLP boosted its position in CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after purchasing an additional 12,233,675 shares during the period. Pacer Advisors Inc. grew its stake in CVS Health by 1,020.7% in the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock valued at $347,984,000 after buying an additional 4,412,882 shares during the last quarter. Amundi grew its position in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Finally, Hamlin Capital Management LLC acquired a new position in shares of CVS Health during the 4th quarter worth about $160,844,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised CVS Health’s price target to $118 from $108 and kept a buy rating, signaling more upside from current levels.
• Positive Sentiment: CVS Caremark announced an agreement with the FTC that it says will improve transparency and affordability in prescription drug pricing, which may help reduce regulatory overhang and support investor confidence. Article Title
• Positive Sentiment: Management also highlighted GLP-1 support expansion across CVS pharmacies, MinuteClinic, and virtual channels, which could strengthen its healthcare services offering and drive more consumer traffic. Article Title
• Neutral Sentiment: Commentary from Jim Cramer and several value-oriented articles reinforced the view that CVS remains a popular large-cap healthcare stock, but these pieces are more sentiment-driven than fundamentally new.
• Negative Sentiment: The FTC settlement also underscores continued scrutiny of CVS Caremark’s rebate and pricing practices, including changes to how it handles drug rebates and future TrumpRx deductible credits, which could pressure margins or business terms over time. Article Title

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.